NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/29/2018 |
| Start Date: | June 29, 2017 |
| End Date: | October 2018 |
| Contact: | Eugene Kennedy, MD |
| Email: | clinicaltrials@linkp.com |
| Phone: | 515-598-2935 |
A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors
This is an open-label Phase I study to evaluate the safety, tolerability, and
pharmacokinetics of escalating oral doses of NLG802, an investigational agent intended to
inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and help the human immune system
attack solid tumor cells more effectively.
pharmacokinetics of escalating oral doses of NLG802, an investigational agent intended to
inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and help the human immune system
attack solid tumor cells more effectively.
Inclusion Criteria:
- Histologically or cytologically confirmed solid tumor cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate hematologic and organ function
- Negative pregnancy test and willingness to utilize contraception among women of
childbearing potential
- Life expectancy at least 4 months
Exclusion Criteria:
- Active or history of medically significant autoimmune disease
- Cytotoxic therapy or investigational agent use within 28 days
- Human immunodeficiency virus (HIV), active hepatitis B or C
- Untreated brain metastases
- Known QT interval prolongation
- Use of concomitant medications with high risk of causing Torsades des Pointes.
- Use of immune suppressive agents within 30 days
- Prior malignancy or therapy for a malignancy within 3 years
We found this trial at
2
sites
Gainesville, Florida 32610
(352) 392-3261
Principal Investigator: Thomas George, MD
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
Click here to add this to my saved trials
Albuquerque, New Mexico 87131
Principal Investigator: Olivier Rixe, MD
Phone: 505-272-0912
Click here to add this to my saved trials